These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

374 related items for PubMed ID: 11451151

  • 21. Preparation and characterization of a set of monoclonal antibodies to TRAIL and TRAIL receptors DR4, DR5, DcR1, and DcR2.
    Liu XS, Zhu Y, Han WN, Li YN, Chen LH, Jia W, Song CJ, Liu F, Yang K, Li Q, Jin BQ.
    Hybrid Hybridomics; 2003 Apr; 22(2):121-5. PubMed ID: 12831538
    [Abstract] [Full Text] [Related]

  • 22. Tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in established and primary glioma cell lines.
    Jaganathan J, Petit JH, Lazio BE, Singh SK, Chin LS.
    Neurosurg Focus; 2002 Sep 15; 13(3):ecp1. PubMed ID: 15844877
    [Abstract] [Full Text] [Related]

  • 23. Membrane expression of DR4, DR5 and caspase-8 levels, but not Mcl-1, determine sensitivity of human myeloma cells to Apo2L/TRAIL.
    Gómez-Benito M, Martinez-Lorenzo MJ, Anel A, Marzo I, Naval J.
    Exp Cell Res; 2007 Jul 01; 313(11):2378-88. PubMed ID: 17462628
    [Abstract] [Full Text] [Related]

  • 24. TRAIL/Apo-2L: mechanisms and clinical applications in cancer.
    Srivastava RK.
    Neoplasia; 2001 Jul 01; 3(6):535-46. PubMed ID: 11774036
    [Abstract] [Full Text] [Related]

  • 25. TRAIL-induced eradication of primary tumour cells from multiple myeloma patient bone marrows is not related to TRAIL receptor expression or prior chemotherapy.
    Lincz LF, Yeh TX, Spencer A.
    Leukemia; 2001 Oct 01; 15(10):1650-7. PubMed ID: 11587225
    [Abstract] [Full Text] [Related]

  • 26. Preclinical differentiation between apparently safe and potentially hepatotoxic applications of TRAIL either alone or in combination with chemotherapeutic drugs.
    Ganten TM, Koschny R, Sykora J, Schulze-Bergkamen H, Büchler P, Haas TL, Schader MB, Untergasser A, Stremmel W, Walczak H.
    Clin Cancer Res; 2006 Apr 15; 12(8):2640-6. PubMed ID: 16638878
    [Abstract] [Full Text] [Related]

  • 27. Role of antiapoptotic proteins in tumor necrosis factor-related apoptosis-inducing ligand and cisplatin-augmented apoptosis.
    Kim JH, Ajaz M, Lokshin A, Lee YJ.
    Clin Cancer Res; 2003 Aug 01; 9(8):3134-41. PubMed ID: 12912965
    [Abstract] [Full Text] [Related]

  • 28. Cotreatment with histone deacetylase inhibitor LAQ824 enhances Apo-2L/tumor necrosis factor-related apoptosis inducing ligand-induced death inducing signaling complex activity and apoptosis of human acute leukemia cells.
    Guo F, Sigua C, Tao J, Bali P, George P, Li Y, Wittmann S, Moscinski L, Atadja P, Bhalla K.
    Cancer Res; 2004 Apr 01; 64(7):2580-9. PubMed ID: 15059915
    [Abstract] [Full Text] [Related]

  • 29. Macrophages from cancer patients: analysis of TRAIL, TRAIL receptors, and colon tumor cell apoptosis.
    Herbeuval JP, Lambert C, Sabido O, Cottier M, Fournel P, Dy M, Genin C.
    J Natl Cancer Inst; 2003 Apr 16; 95(8):611-21. PubMed ID: 12697854
    [Abstract] [Full Text] [Related]

  • 30. Fas-associated death domain protein (FADD) and caspase-8 mediate up-regulation of c-Fos by Fas ligand and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) via a FLICE inhibitory protein (FLIP)-regulated pathway.
    Siegmund D, Mauri D, Peters N, Juo P, Thome M, Reichwein M, Blenis J, Scheurich P, Tschopp J, Wajant H.
    J Biol Chem; 2001 Aug 31; 276(35):32585-90. PubMed ID: 11384965
    [Abstract] [Full Text] [Related]

  • 31. Sensitivity of prostate cells to TRAIL-induced apoptosis increases with tumor progression: DR5 and caspase 8 are key players.
    Hesry V, Piquet-Pellorce C, Travert M, Donaghy L, Jégou B, Patard JJ, Guillaudeux T.
    Prostate; 2006 Jun 15; 66(9):987-95. PubMed ID: 16541419
    [Abstract] [Full Text] [Related]

  • 32. Apoptosis control by death and decoy receptors.
    Ashkenazi A, Dixit VM.
    Curr Opin Cell Biol; 1999 Apr 15; 11(2):255-60. PubMed ID: 10209153
    [Abstract] [Full Text] [Related]

  • 33. Sensitization of tumor cells to Apo2 ligand/TRAIL-induced apoptosis by inhibition of casein kinase II.
    Ravi R, Bedi A.
    Cancer Res; 2002 Aug 01; 62(15):4180-5. PubMed ID: 12154014
    [Abstract] [Full Text] [Related]

  • 34. Expression of tumour necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) receptors and sensitivity to TRAIL-induced apoptosis in primary B-cell acute lymphoblastic leukaemia cells.
    Clodi K, Wimmer D, Li Y, Goodwin R, Jaeger U, Mann G, Gadner H, Younes A.
    Br J Haematol; 2000 Nov 01; 111(2):580-6. PubMed ID: 11122106
    [Abstract] [Full Text] [Related]

  • 35. Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL.
    Emery JG, McDonnell P, Burke MB, Deen KC, Lyn S, Silverman C, Dul E, Appelbaum ER, Eichman C, DiPrinzio R, Dodds RA, James IE, Rosenberg M, Lee JC, Young PR.
    J Biol Chem; 1998 Jun 05; 273(23):14363-7. PubMed ID: 9603945
    [Abstract] [Full Text] [Related]

  • 36. Sensitization of cells to TRAIL-induced apoptosis by decoy receptor 3.
    Wu YY, Chang YC, Hsu TL, Hsieh SL, Lai MZ.
    J Biol Chem; 2004 Oct 15; 279(42):44211-8. PubMed ID: 15475369
    [Abstract] [Full Text] [Related]

  • 37. Pretreatment with paclitaxel enhances apo-2 ligand/tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis of prostate cancer cells by inducing death receptors 4 and 5 protein levels.
    Nimmanapalli R, Perkins CL, Orlando M, O'Bryan E, Nguyen D, Bhalla KN.
    Cancer Res; 2001 Jan 15; 61(2):759-63. PubMed ID: 11212279
    [Abstract] [Full Text] [Related]

  • 38. Mechanisms of resistance to TRAIL-induced apoptosis in cancer.
    Zhang L, Fang B.
    Cancer Gene Ther; 2005 Mar 15; 12(3):228-37. PubMed ID: 15550937
    [Abstract] [Full Text] [Related]

  • 39. Apo2L/TRAIL differentially modulates the apoptotic effects of sulindac and a COX-2 selective non-steroidal anti-inflammatory agent in Bax-deficient cells.
    He Q, Luo X, Huang Y, Sheikh MS.
    Oncogene; 2002 Sep 05; 21(39):6032-40. PubMed ID: 12203115
    [Abstract] [Full Text] [Related]

  • 40. Effects and expression of TRAIL and its apoptosis-promoting receptors in human pancreatic cancer.
    Ozawa F, Friess H, Kleeff J, Xu ZW, Zimmermann A, Sheikh MS, Büchler MW.
    Cancer Lett; 2001 Feb 10; 163(1):71-81. PubMed ID: 11163110
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 19.